KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Emergent BioSolutions (EBS) Gross Margin (2016 - 2025)

Historic Gross Margin for Emergent BioSolutions (EBS) over the last 17 years, with Q3 2025 value amounting to 62.83%.

  • Emergent BioSolutions' Gross Margin rose 45600.0% to 62.83% in Q3 2025 from the same period last year, while for Sep 2025 it was 105.83%, marking a year-over-year increase of 169600.0%. This contributed to the annual value of 73.55% for FY2024, which is 26800.0% up from last year.
  • Latest data reveals that Emergent BioSolutions reported Gross Margin of 62.83% as of Q3 2025, which was up 45600.0% from 52.52% recorded in Q2 2025.
  • In the past 5 years, Emergent BioSolutions' Gross Margin registered a high of 247.56% during Q4 2024, and its lowest value of 6.94% during Q1 2023.
  • Moreover, its 5-year median value for Gross Margin was 60.12% (2025), whereas its average is 76.16%.
  • Its Gross Margin has fluctuated over the past 5 years, first surged by 1219100bps in 2022, then crashed by -667200bps in 2023.
  • Emergent BioSolutions' Gross Margin (Quarter) stood at 39.9% in 2021, then skyrocketed by 306bps to 161.81% in 2022, then grew by 10bps to 177.62% in 2023, then skyrocketed by 39bps to 247.56% in 2024, then tumbled by -75bps to 62.83% in 2025.
  • Its Gross Margin was 62.83% in Q3 2025, compared to 52.52% in Q2 2025 and 60.17% in Q1 2025.